Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
32
PHAR Quote, Financials, Valuation and Earnings
Last price:
$16.53
Seasonality move
:
-4.54%
Day range:
$15.79 - $16.60
52-week range:
$7.50 - $21.34
Dividend yield:
0%
P/E ratio:
1,144.76x
P/S ratio:
3.08x
P/B ratio:
4.24x
Volume:
23.5K
Avg. volume:
33.4K
1-year change:
79%
Market cap:
$1.1B
Revenue:
$296.7M
EPS (TTM):
$0.01
Analysts' Opinion
-
Consensus RatingPharming Group NV has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $31.00, Pharming Group NV has an estimated upside of 89.37% from its current price of $16.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $16.37.
Fair Value
-
According to the consensus of 3 analysts, Pharming Group NV has 89.37% upside to fair value with a price target of $31.00 per share.
PHAR vs. S&P 500
-
Over the past 5 trading days, Pharming Group NV has underperformed the S&P 500 by -0.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pharming Group NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pharming Group NV has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Pharming Group NV reported revenues of $96.9M.
Earnings Growth
-
Pharming Group NV has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Pharming Group NV reported earnings per share of $0.11.
Enterprise value:
1.1B
EV / Invested capital:
--
Price / LTM sales:
3.08x
EV / EBIT:
31.94x
EV / Revenue:
3.00x
PEG ratio (5yr expected):
-2.22x
EV / Free cash flow:
22.16x
Price / Operating cash flow:
22.81x
Enterprise value / EBITDA:
24.30x
Gross Profit (TTM):
$323.2M
Return On Assets:
0.21%
Net Income Margin (TTM):
0.25%
Return On Equity:
0.39%
Return On Invested Capital:
0.25%
Operating Margin:
16.34%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $218.9M | $286.4M | $362.4M | $75.1M | $96.9M | |
| Gross Profit | $187.5M | $248.4M | $323.2M | $68.2M | $89.8M | |
| Operating Income | -$38.5M | -$16.7M | $34M | $3.3M | $15.8M | |
| EBITDA | -$23.1M | -$681.6K | $44.7M | $6.1M | $18.5M | |
| Diluted EPS | -$0.34 | -$0.26 | $0.01 | -$0.02 | $0.11 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $242.2M | $252M | $291.7M | $282.2M | $277.6M | |
| Total Assets | $400.9M | $382.3M | $436.5M | $425.5M | $473.8M | |
| Current Liabilities | $46.7M | $46.7M | $68.1M | $79.8M | $87.9M | |
| Total Liabilities | $207.4M | $182.1M | $226.5M | $199.7M | $209.1M | |
| Total Equity | $193.5M | $200.3M | $209.9M | $225.8M | $264.6M | |
| Total Debt | $164.8M | $139.2M | $164M | $127.1M | $130.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.6M | -$968.8K | $49.6M | $9.7M | $30M | |
| Cash From Investing | -$126M | $37.5M | $8.7M | $4.4M | -$2.3M | |
| Cash From Financing | $4.3M | -$31.2M | $11.1M | -$1.5M | $11.9M | |
| Free Cash Flow | -$29.1M | -$2M | $49M | $9.3M | $29.9M | |
PHAR
Sector
Market Cap
$1.1B
$25.8M
Price % of 52-Week High
76.71%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
-1.64%
-1.64%
1-Year Price Total Return
79.01%
-18.88%
Beta (5-Year)
-0.009
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$16.58
200-day SMA
Buy
Level
$14.18
Bollinger Bands (100)
Sell
Level
14.65 - 18.29
Chaikin Money Flow
Buy
Level
2.3K
20-day SMA
Sell
Level
$16.79
Relative Strength Index (RSI14)
Sell
Level
44.33
ADX Line
Sell
Level
17.5
Williams %R
Neutral
Level
-49.0964
50-day SMA
Sell
Level
$17.50
MACD (12, 26)
Buy
Level
4.53
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
46.5K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5101)
Buy
CA Score
(Annual)
Level (-0.2455)
Buy
Beneish M-Score
(Annual)
Level (-2.2962)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.0742)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
Stock Forecast FAQ
In the current month, PHAR has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PHAR average analyst price target in the past 3 months is $31.00.
-
Where Will Pharming Group NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pharming Group NV share price will rise to $31.00 per share over the next 12 months.
-
What Do Analysts Say About Pharming Group NV?
Analysts are divided on their view about Pharming Group NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pharming Group NV is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Pharming Group NV's Price Target?
The price target for Pharming Group NV over the next 1-year time period is forecast to be $31.00 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PHAR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pharming Group NV is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PHAR?
You can purchase shares of Pharming Group NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pharming Group NV shares.
-
What Is The Pharming Group NV Share Price Today?
Pharming Group NV was last trading at $16.53 per share. This represents the most recent stock quote for Pharming Group NV. Yesterday, Pharming Group NV closed at $16.37 per share.
-
How To Buy Pharming Group NV Stock Online?
In order to purchase Pharming Group NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get PHAR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PHAR
Sector
P/E ratio
1,144.76x
23.44x
PEG ratio
-2.22x
-0.01x
P/B ratio
4.24x
1.81x
Price / LTM sales
3.08x
1.56x
Growth Metrics
PHAR
Sector
Revenue growth
29.05%
3.27%
Earnings growth
817.11%
9.66%
Revenue (5-year growth)
9.42%
6.43%
Earnings forecast
$0.01
-$0.20
Profitability
PHAR
Sector
Profitability FY 2024
$250.3M
$2.3M
Return on invested capital
0.25%
-33.49%
Return on assets
0.21%
-29.74%
Return on equity
0.39%
-39.33%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
5
Balance Sheet
PHAR
Sector
Total cash
$166.9M
$24.2M
Short term investments
$112.9M
$23.8M
Total assets
$411.4M
$71.1M
Long term debt
$130.9M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
